⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888604 | 0.69 | — | — | |
| SCHEMBL1852444 | 0.65 | — | — | |
| SCHEMBL1856839 | 0.65 | — | — | |
| SCHEMBL4927571 | 0.65 | — | — | |
| SCHEMBL18343016 | 0.65 | — | — | |
| SCHEMBL4931186 | 0.64 | — | — | |
| SCHEMBL1853748 | 0.64 | — | — | |
| SCHEMBL1854770 | 0.62 | CYP1A2 (0.43) | — | |
| SCHEMBL12471156 | 0.61 | HRH4 (0.31) | — | |
| SCHEMBL12471163 | 0.61 | CYP19A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | claimed |
| EP-3893871-B1 | BENZIMIDAZOLONE DERIVATIVES, AND ANALOGUES THEREOF, AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-04-10 | — | — | EP | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| CN-110769821-B | Spiro indolines as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | UCBBiopharma Srl (BE) | 2022-10-04 | — | — | US | disclosed |
| US-20210380573-A1 | Benzimidazolone Derivatives, and Analogues Thereof, as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-12-09 | — | — | US | disclosed |
| EP-3894003-A1 | FUNCTIONALISED AMINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2021-10-20 | — | — | EP | disclosed |
| EP-3893871-A1 | BENZIMIDAZOLONE DERIVATIVES, AND ANALOGUES THEREOF, AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2021-10-20 | — | — | EP | disclosed |
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-07-29 | — | — | US | disclosed |
| EP-2211620-A1 | THERAPEUTIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009054941-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |